Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
Hansa Biopharma (NASDAQ Stockholm: HNSA) has appointed Dr. Richard Philipson as Chief Medical Officer (CMO), effective July 14, 2025. Dr. Philipson brings over 25 years of industry experience and will report to CEO Renée Aguiar-Lucander as a member of the Executive Committee.
Dr. Philipson's extensive background includes serving as CMO at Calliditas Therapeutics, 16 years at GlaxoSmithKline including leadership in the Rare Diseases Unit, and positions at Takeda and Trizell. His track record includes contributing to four product approvals in rare disease and gene therapy, along with expertise in building clinical development programs across all phases.
Hansa Biopharma (NASDAQ Stoccolma: HNSA) ha nominato Dr. Richard Philipson come Chief Medical Officer (CMO), con decorrenza dal 14 luglio 2025. Il Dr. Philipson vanta oltre 25 anni di esperienza nel settore e riporterà direttamente al CEO Renée Aguiar-Lucander, entrando a far parte del Comitato Esecutivo.
Il suo ampio background comprende il ruolo di CMO presso Calliditas Therapeutics, 16 anni in GlaxoSmithKline con responsabilità nella Rare Diseases Unit, oltre a posizioni in Takeda e Trizell. Tra i suoi successi, ha contribuito a quattro approvazioni di prodotti in malattie rare e terapia genica, oltre ad avere competenze nella costruzione di programmi di sviluppo clinico in tutte le fasi.
Hansa Biopharma (NASDAQ Estocolmo: HNSA) ha nombrado a Dr. Richard Philipson como Director Médico (CMO), con efecto a partir del 14 de julio de 2025. El Dr. Philipson aporta más de 25 años de experiencia en la industria y reportará al CEO Renée Aguiar-Lucander como miembro del Comité Ejecutivo.
Su amplia trayectoria incluye haber sido CMO en Calliditas Therapeutics, 16 años en GlaxoSmithKline liderando la Unidad de Enfermedades Raras, y cargos en Takeda y Trizell. Su historial incluye la contribución a cuatro aprobaciones de productos en enfermedades raras y terapia génica, junto con experiencia en el desarrollo de programas clínicos en todas las fases.
한사 바이오파마 (NASDAQ 스톡홀름: HNSA)는 리처드 필립슨 박사를 2025년 7월 14일부터 최고 의료 책임자(CMO)로 임명했습니다. 필립슨 박사는 25년 이상의 업계 경력을 보유하고 있으며, CEO 르네 아귀아르-루칸더에게 보고하며 경영위원회의 일원으로 활동할 예정입니다.
필립슨 박사의 폭넓은 경력에는 Calliditas Therapeutics의 CMO, 글락소스미스클라인에서 16년 동안 희귀질환 부서 리더십, 그리고 Takeda와 Trizell에서의 직책이 포함됩니다. 그는 희귀질환 및 유전자 치료 분야에서 네 건의 제품 승인에 기여했으며, 모든 단계의 임상 개발 프로그램 구축에 대한 전문성을 갖추고 있습니다.
Hansa Biopharma (NASDAQ Stockholm : HNSA) a nommé Dr Richard Philipson au poste de Chief Medical Officer (CMO), à compter du 14 juillet 2025. Le Dr Philipson apporte plus de 25 ans d'expérience dans l'industrie et reportera directement à la CEO Renée Aguiar-Lucander en tant que membre du Comité Exécutif.
Son parcours étendu inclut son rôle de CMO chez Calliditas Therapeutics, 16 ans chez GlaxoSmithKline avec des responsabilités dans l'unité des maladies rares, ainsi que des postes chez Takeda et Trizell. Il a contribué à quatre autorisations de produits dans les domaines des maladies rares et de la thérapie génique, avec une expertise dans la mise en place de programmes de développement clinique à tous les stades.
Hansa Biopharma (NASDAQ Stockholm: HNSA) hat Dr. Richard Philipson zum Chief Medical Officer (CMO) ernannt, mit Wirkung zum 14. Juli 2025. Dr. Philipson bringt über 25 Jahre Branchenerfahrung mit und wird direkt an CEO Renée Aguiar-Lucander berichten sowie Mitglied des Executive Committee sein.
Sein umfangreicher Hintergrund umfasst die Tätigkeit als CMO bei Calliditas Therapeutics, 16 Jahre bei GlaxoSmithKline mit Führungsaufgaben in der Rare Diseases Unit sowie Positionen bei Takeda und Trizell. Er hat maßgeblich zu vier Produktzulassungen im Bereich seltener Krankheiten und Gentherapie beigetragen und verfügt über Expertise im Aufbau klinischer Entwicklungsprogramme in allen Phasen.
- Appointment of highly experienced CMO with 25+ years of industry expertise
- New CMO brings track record of 4 successful product approvals
- Extensive experience in rare diseases and gene therapy development
- Strong background in regulatory strategy and clinical development across all phases
- None.
Dr Philipson has over 25 years of industry experience and a successful track record in drug development, providing clinical leadership resulting in four product approvals, including in rare disease and gene therapy, and comes with expertise and success in building high-functioning teams, building pipelines and executing clinical development programs across all phases of development. He also brings in-depth knowledge of regulatory strategy in drug development. Dr Philipson most recently was CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. He also has experience from Takeda, and a 4-year period as CMO at Trizell.
"We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander.
"I am excited to have the opportunity to join Hansa at this stage of the company's development. I look forward to working with the Hansa team and leveraging my experience from prior roles to support upcoming regulatory submissions and help build a strategic development plan for future indications," said Dr Philipson.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB,
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
20250708-CMO_ENG_FINAL |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-302499849.html
SOURCE Hansa Biopharma AB
FAQ
Who is the new Chief Medical Officer of Hansa Biopharma (HNSA)?
What is Dr. Richard Philipson's experience before joining Hansa Biopharma (HNSA)?
When will Dr. Philipson start his role as CMO at Hansa Biopharma?
What will be Dr. Philipson's responsibilities at Hansa Biopharma (HNSA)?
